Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm

Recent insight into the pathophysiology of severe coronavirus disease 2019 (COVID-19) has implicated hyperactivation of the immune response, resulting in a “cytokine storm,” which can lead to excessive immune-cell infiltration of the lungs, alveolar damage, decreased lung function, and death. Severa...

Descripción completa

Detalles Bibliográficos
Autores principales: Langmuir, Peter, Yeleswaram, Swamy, Smith, Paul, Knorr, Barbara, Squier, Peg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Delaware Academy of Medicine / Delaware Public Health Association 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389815/
https://www.ncbi.nlm.nih.gov/pubmed/34467111
http://dx.doi.org/10.32481/djph.2020.07.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389815/
https://www.ncbi.nlm.nih.gov/pubmed/34467111
http://dx.doi.org/10.32481/djph.2020.07.015

Ejemplares similares